RS
VTGN icon

R Squared’s VistaGen Therapeutics VTGN Stock Holding History

R Squared’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27K Buy
+27,745
New +$16.7K ﹤0.01% 508
2025
Q1 		– Sell
-8,610
Closed -$25.4K – 1503
2024
Q4 		$25.4K Buy
+8,610
New +$24.2K 0.02% 775

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

R Squared's VTGN Position: Q2 2026 in Review

R Squared opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 27,745 shares worth $6.27K. The stake represents ﹤0.01% of the portfolio and ranks #508 among its holdings. This is a return to the name: R Squared previously reported a position in VTGN as recently as Q4 2024.

R Squared first reported a position in VTGN in Q4 2024 and has held it in 2 quarters since. The position peaked at $25.4K in Q4 2024. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • R Squared held 27,745 shares of VistaGen Therapeutics worth $6.27K as of Q2 2026.
  • VistaGen Therapeutics was a new R Squared position in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of R Squared's portfolio in Q2 2026, its #508 holding.
  • R Squared first reported a position in VistaGen Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • R Squared's VistaGen Therapeutics position peaked at $25.4K in Q4 2024.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.